CC 90005

Drug Profile

CC 90005

Alternative Names: CC-90005

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Antipsoriatics
  • Mechanism of Action Protein kinase C theta modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 26 Feb 2016 Celgene Corporation terminates a phase I trial in Plaque psoriasis in USA (PO) (NCT02502188)
  • 24 Jul 2015 Celgene Corporation plans a phase I for Healthy volunteers and patients with Plaque psoriasis in USA (NCT02502188)
  • 01 Jul 2015 Phase-I clinical trials in Plaque psoriasis in USA (PO) (NCT02502188)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top